Grey Wolf Animal Health is pleased to announce the launch of SEDAJECT™ and ATAJECT™ in the Canadian veterinary market.
SEDAJECT™ (dexmedetomidine hydrochloride injection, 0.5 mg/ml) is a sedative and analgesic used in dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures. It is also indicated for use as a preanesthetic to general anesthesia in dogs and cats.
ATAJECT™ (atipamezole hydrochloride injection, 5.0 mg/ml) is indicated for the reversal of the clinical effects of the sedative and analgesic agents dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs.
SEDAJECT™ and ATAJECT™ were developed by Vetpharma Animal Health S.L. and are manufactured in Spain. Both products are sold in over ten countries in Europe including Spain, France and Belgium.
For more information, contact your local Grey Wolf rep or your buying group directly.